Author of

• 25950

  +

  P2.13 - Targeted Therapy (Not CME Accredited Session) (ID 962)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 27190

    +

    P2.13-16 - Preference of Adjuvant Treatments for EGFR-Mutant Resected NSCLC Patients: Results of a National-Wide Survey in China (ID 13390)

    16:45 - 18:00  |  Author(s): Minzhang Guo
    • Abstract
    • Slides

    Background
    

    EGFR mutated patients represent half of NSCLC cases in China. ADJUVANT study (NCT01405079), a published multicenter RCT, showed that EGFR-TKIs were associated with significant longer DFS than chemotherapy in stage II to IIIA resected NSCLC patients. We sought to investigate the preference on adjuvant EGFR-TKI of the surgeons specializing on NSCLC in China by conducting an online national-wide survey.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    The question ‘would you recommend EGFR-TKIs as adjuvant therapy in postoperative patients with EGFR mutation? -Yes; No’ was included on an online survey system. Interviewee personal information was also collected. Logistic regression model was conducted to explore factors associated with the choices.

    4c3880bb027f159e801041b1021e88e8 Result
    

    We received 732 responses from lung cancer surgeons from 30 provinces of China, 618 (84.43%) doctors were from department of general thoracic surgery and 114 (15.57%) surgeons from department of thoracic oncology surgery, 660 (90.16%) were from tertiary hospitals and 65 (8.88%) from the secondary ones. The interviewees consisted of 93 (12.70%) master candidates, 15 (2.05%) doctoral candidates, 98 (13.39%) residents, 217 (29.64%) attending doctors, 174 (23.77%) associate chiefs of surgeon and 135 (18.44%) chiefs of surgeon. As a result, 572 (78.1%) surgeons selected “Yes”, 143 (19.5%) selected “No”, and the rest abstained. Logistic regression analysis revealed that the result was not influenced by different career duration, location, economic status of living, hospital grade, department type, etc.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    This national-wide large sample survey showed that recommending EGFR-TKIs as adjuvant therapy for postoperative EGFR-mutant NSCLC patients was widely supported by specialists in lung cancer in China.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.